NASDAQ:IRWD - Ironwood Pharmaceuticals Stock Price, News & Analysis

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its quarterly earnings data on Tuesday, July, 30th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.07) by $0.15. The biotechnology company earned $102.22 million during the quarter, compared to the consensus estimate of $89.28 million. The company's revenue was up 26.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.22) earnings per share. View Ironwood Pharmaceuticals' Earnings History.

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals updated its FY 2019 earnings guidance on Tuesday, July, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $370-390 million, compared to the consensus revenue estimate of $374.63 million.

11 brokerages have issued 1 year price objectives for Ironwood Pharmaceuticals' shares. Their forecasts range from $12.00 to $20.00. On average, they expect Ironwood Pharmaceuticals' stock price to reach $15.05 in the next twelve months. This suggests a possible upside of 58.1% from the stock's current price. View Analyst Price Targets for Ironwood Pharmaceuticals.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ironwood Pharmaceuticals.

Media headlines about IRWD stock have been trending negative on Tuesday, according to InfoTrie. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ironwood Pharmaceuticals earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Ironwood Pharmaceuticals.

Some companies that are related to Ironwood Pharmaceuticals include Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), The Medicines (MDCO), United Therapeutics (UTHR), Allakos (ALLK), Nektar Therapeutics (NKTR), FibroGen (FGEN), Alkermes (ALKS), Mirati Therapeutics (MRTX), Evotec (EVTCY), Taro Pharmaceutical Industries (TARO), Global Blood Therapeutics (GBT) and BridgeBio Pharma (BBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Allergan (AGN) and Continental Resources (CLR).

Ironwood Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.97%), Brown Capital Management LLC (7.88%), Janus Henderson Group PLC (4.85%), Janus Henderson Group PLC (4.85%), EcoR1 Capital LLC (2.99%) and Westfield Capital Management Co. LP (1.53%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

IRWD stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Canada Pension Plan Investment Board, D. E. Shaw & Co. Inc., Morgan Stanley, Cubist Systematic Strategies LLC, Marshall Wace LLP, BNP Paribas Arbitrage SA and NumerixS Investment Technologies Inc. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals.

IRWD stock was acquired by a variety of institutional investors in the last quarter, including Brown Capital Management LLC, Peregrine Capital Management LLC, Nuveen Asset Management LLC, Janus Henderson Group PLC, Janus Henderson Group PLC, Vanguard Group Inc., Westfield Capital Management Co. LP and Jacobs Levy Equity Management Inc.. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IRWD stock can currently be purchased for approximately $9.52.

Ironwood Pharmaceuticals has a market capitalization of $1.49 billion and generates $346.64 million in revenue each year. The biotechnology company earns $-282,370,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. Ironwood Pharmaceuticals employs 515 workers across the globe.View Additional Information About Ironwood Pharmaceuticals.

The official website for Ironwood Pharmaceuticals is http://www.ironwoodpharma.com/.

Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]